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a b s t r a c t
Foot-and-mouth disease virus (FMDV) causes a highly contagious disease of cloven-hoofed animals. We
have previously demonstrated that a replication-defective human adenovirus 5 vector carrying the
FMDV capsid coding region of serotype A24 Cruzeiro (Ad5-CI-A24-2B) protects swine and cattle against
FMDV challenge by 7 days post-vaccination. However, since relatively large amounts of Ad5-CI-A24-2B
are required to induce protection this strategy could be costly for livestock production. Poly ICLC is a
synthetic double stranded RNA that activates multiple innate and adaptive immune pathways. In this
study, we have tested for the ﬁrst time, the adjuvant effect of poly ICLC in combination with Ad5-CI-A24-
2B in swine. We found that the combination resulted in a reduction of the vaccine protective dose by 80-
fold. Interestingly, the lowest dose of Ad5-CI-A24-2B plus 1 mg of poly ICLC protected animals against
challenge even in the absence of detectable FMDV-speciﬁc neutralizing antibodies at the time of
challenge.
Published by Elsevier Inc.
Introduction
Foot-and-mouth disease (FMD) is a highly contagious viral dis-
ease of cloven-hoofed animals that can have a signiﬁcant economic
impact on both FMD-free countries and countries in which the
disease is enzootic. While FMD does not result in high mortality it
can cause signiﬁcant morbidity effecting animal growth, milk pro-
duction, etc. The disease results in well characterized clinical signs
consisting of fever, lameness and vesicular lesions in the mouth,
tongue, nose, feet and teats (Grubman and Baxt, 2004). Since FMD is
a “listed disease” by the World Organization of Animal Health (OIE)
(OIE, 2004), FMD-free OIE member countries impose trade restric-
tions on susceptible animals and their products from countries in
which the disease is present, resulting in considerable economic and
social consequences.
The etiologic agent, FMD virus (FMDV), that belongs to the
Aphthovirus genus, family Picornaviridae, is antigenically variable
and consists of 7 serotypes and multiple subtypes and strains
within each serotype (Grubman and Baxt, 2004). The virus con-
tains a single-stranded positive-sense RNA genome surrounded by
an icosahedral capsid composed of 60 copies each of 4 structural
proteins. The viral genome codes for the 4 structural proteins
(VP1–VP4) as well as 10 nonstructural (NS) proteins required at
different stages of viral replication (Grubman and Baxt, 2004;
Mason et al., 2003).
FMD outbreaks are controlled by restriction of animal move-
ment, decontamination of infected premises, and slaughter of
infected and in-contact animals. Vaccination with an inactivated
whole virus vaccine is also used in enzootic countries. However,
vaccination is often not used in previously FMD-free countries
since current OIE regulations favor slaughter or vaccination
followed by slaughter, rather than only vaccination as the
approach to most rapidly regain FMD-free status and thus resume
international trade (Grubman and Baxt, 2004).
While the current inactivated vaccine has been successfully
used to eliminate FMD from Western Europe and parts of South
America, there are a number of limitations in its use including
difﬁculty in distinguishing infected from vaccinated animals
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(DIVA), the requirement of an expensive high-containment facility
for vaccine production, and the possibility of escape of live or
inadequately inactivated virus from production facilities. As a
result investigators have attempted to develop alternative vaccine
approaches (Mason and Grubman, 2008). The use of replication-
defective human adenovirus (Ad5-) to deliver FMD vaccines has
been reported by different groups. Du et al. (2007, 2008a, 2008b)
have tested Ad5 vectors expressing multiple VP1 epitopes com-
bined with immunomodulatory molecules. However, several
boosts were required to achieve complete protection, even in
mice. On the other hand, we have successfully used a similar
approach to deliver FMDV empty capsids (Ad5-FMD) and effec-
tively addressed most of the concerns of the inactivated vaccine in
the FMDV natural host. Our Ad5-FMD vaccine contains the FMDV
capsid-coding region, P1-2A, as well as the coding region for the
viral protease 3Cpro, that is required for processing P1-2A into the
individual capsid proteins (Mayr et al., 1999, 2001). One inocula-
tion of this ﬁrst generation Ad5-FMD vaccine resulted in complete
protection from challenge of swine and cattle as early as 7 days
post-vaccination (Moraes et al., 2002; Pacheco et al., 2005). More
recently in collaboration with the Department of Homeland
Security, and a partner company, GenVec, Inc., this platform has
been further developed for production purposes (Grubman et al.,
2010) and in June of 2012 the Center for Veterinary Biologics,
Animal Plant and Health Inspection Service, USDA, granted a
conditional license for use of the Ad5-FMDV serotype A24 Cruzeiro
vaccine in cattle in an emergency situation (Grubman et al., 2012).
One of the limitations of the Ad5-FMD approach is that it
requires a relatively high protective dose which is problematic for
utilization as a veterinary vaccine. In an effort to address this
concern, we have evaluated several approaches. We constructed a
second-generation Ad5-FMD vaccine (Ad5-CI-A24-2B) which con-
tained the P1-2A coding region of FMDV A24 and incorporated the
full length 2B coding region of the same serotype, in addition to
the partial 3B and full length 3Cpro coding regions of FMDV A12
present in our ﬁrst-generation vaccine (Pena et al., 2008). The 2B
protein is involved in the rearrangement of cellular membranes
that act as sites for picornavirus replication and capsid assembly
(Aldabe and Carrasco, 1995; Cho et al., 1994; Suhy et al., 2000; de
Jong et al., 2002; Monaghan et al., 2004; Buenz and Howe, 2006;
Moffat et al., 2005; García-Briones et al., 2006). Our hypothesis
was that creation of an intracellular milieu that resembled natural
infection would enhance capsid formation and stability. Inocula-
tion of swine or cattle with this vector containing the full length
2B region enhanced vaccine efﬁcacy and induced a more robust
cell-mediated immune response (Pena et al., 2008; Moraes et al.,
2011). More recently we showed that subcutaneous (sc) inocula-
tion at 2 sites on either side of the neck compared to intramus-
cular inoculation (im) at one site resulted in at least an additional
25-fold dose-sparing (protective at 2108 pfu/animal as com-
pared to 5109 pfu/animal) (Grubman et al., 2012). These results
indicated that there is a strict correlation between the vaccine
dose, route of administration and induced protection, as pre-
viously reported for other Ad vector-based vaccines (Tatsis and
Ertl, 2004).
An additional approach to enhance the immune response
induced by a vaccine is the inclusion of an adjuvant in the vaccine
formulation. Adjuvants can signiﬁcantly enhance the maturation
of antigen-presenting dendritic cells (DCs) and the antigen speciﬁc
cellular response (Pulendran and Ahmed, 2006; Kool et al., 2008).
Poly ICLC is a synthetic, double-stranded polyriboinosinic-poly-
ribocytidylic acid molecule stabilized with poly-L-lysine and car-
boxymethyl cellulose which has enhanced biostability in animals,
as compared to poly IC (Nordlund et al., 1970) and is a known toll-
like receptor 3 (TLR3) and MDA-5 agonist that can activate
multiple innate immune pathways (Meylan and Tschopp, 2006;
Stahl-Hennig et al., 2009). Moreover, poly IC enhances DC matura-
tion and B cell activation, leading to induction of a potent adaptive
immune response when combined with protein antigens
(Stahl-Hennig et al., 2009; Flynn et al., 2011) and also potentiates
differentiation of effector CD8þ T cells (Wiltrout et al., 1985; Ngoi
et al., 2008). In rodents and primates, poly ICLC is a strong
interferon alpha (IFN-α) inducer and provides antiviral and adju-
vant activity (Levy et al., 1975; Harrington et al., 1979; Caskey et al.,
2011; Tenbusch et al., 2012). In addition, treatment with poly IC
has been effective in providing protection in animal models
against a number of viral infections (Houston et al., 1976;
Stephen et al., 1977, 1979; Baer et al., 1979; Kende, 1985; Kende
et al., 1987; Stahl-Hennig et al., 2009; Li et al., 2011; Levy et al.,
1976), as well as inducing rapid innate protection against FMDV in
swine (Dias et al., 2012). Furthermore, it has been recently shown
that poly IC has an adjuvant effect when combined with an FMD
multiepitope protein or inactivated FMD vaccines (Cao et al., 2012,
2013, 2014; Zhou et al., 2014).
In this study we examined the effectiveness of poly ICLC when
combined with our second-generation Ad5-CI-A24-2B vaccine
delivered sc at 2 sites. We demonstrate that vaccination with the
combination reduces the vaccine protective dose approximately 80-
fold as compared to administration of vaccine alone. Interestingly,
the enhanced efﬁcacy of the combination approach correlated with
a stronger antigen speciﬁc cell-mediated immune response.
Results
Poly ICLC has been used as an adjuvant in some animal models,
but its use in vaccine formulations to immunize large animals has
never been described. We performed a preliminary study to
estimate the dose of poly ICLC required to induce an adjuvant
effect when combined with an Ad5-FMD vaccine (experiment ♯1).
We compared the effect of combining 1 or 4 mg poly ICLC with a
suboptimal dose of Ad5-CI-A24-2B vaccine (4107 pfu/animal).
Twenty-one days postvaccination (dpv) animals were challenged.
All the control animals (Ad5-Blue vaccinated) developed severe
disease by 2 days postchallenge (dpc) with clinical scores of 16–17
(maximum score possible is 17). As expected, the three animals
treated with a dose of 2108 pfu/animal of Ad5-CI-A24-2B were
fully protected with no detectable viremia, virus shedding, or viral
RNA in serum (Table 1). In contrast, a reduction in the vaccine dose
to 4107 pfu/animal, only induced partial protection and all three
animals developed clinical signs between 3–6 dpc, but with
reduced severity (clinical score 1–3). Only viral RNA was detected
in 2 of the 3 animals by RT-PCR, a more sensitive method than
conventional virus detection. Interestingly, a combination of
4107 pfu/animal vaccine with 1 or 4 mg of poly ICLC resulted
in enhanced protection. One animal in each group was fully
protected and the other 2 developed milder disease as compared
to the group inoculated with vaccine alone. Only one out of the six
animals had detectable viral RNA. No signiﬁcant differences were
observed in the clinical or antibody responses. Based on these
results we decided to use 1 mg of poly ICLC to further examine its
effectiveness in enhancing the efﬁcacy of the Ad5-CI-A24-2B
vaccine.
Poly ICLC improves humoral immune response induced by
Ad5-CI-A24-2B vaccine
Following the preliminary study, we performed another experi-
ment (experiment ♯2) and compared the efﬁcacy of a 20-fold lower
vaccine dose in the presence or absence of 1 mg poly ICLC (Table 2).
Four groups of 3 animals each were vaccinated with either 2108 pfu
Ad5-Blue vector control, 2108 pfu Ad5-CI-A24-2B, or 1107 pfu
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Ad5-CI-A24-2B in the presence or absence of 1 mg poly ICLC, followed
by challenge with FMDV at 21 dpv.
In the group inoculated with 2108 pfu of the Ad5-CI-A24-2B
vaccine, all animals developed serum neutralizing (SN) antibodies
starting at 7 dpv with a peak at 14 dpv (Fig. 1; Table 2). Reducing the
vaccine dose to 1107 pfu resulted in signiﬁcantly lower levels of SN
antibodies that were only detected by 21 dpv, and one animal, ♯14,
did not show any response before challenge (Table 2). In contrast,
animals vaccinated with the combination of the low dose vaccine
and poly ICLC developed SN antibodies that were detected starting at
7 dpv with a maximum at 14 dpv that was statistically signiﬁcant
(Po0.05), suggesting that poly ICLC had an adjuvant effect on the
humoral immune response (Fig. 1). Nevertheless, the level of SN
antibodies prior to challenge in these animals was lower than in the
pigs inoculated with the highest dose (2108 pfu) of vaccine alone.
All animals in the control group developed viremia by 1 dpc
lasting for 3–4 days, while clinical disease was evident by 2 dpc
(Fig. 2A; Table 2). None of the animals in the high dose group
(2108 pfu) developed clinical disease or had virus in serum or
nasal swabs, as assayed by either virus isolation or viral RNA by
rRT-PCR (Fig. 2B; Table 2). With the exception of one animal (♯2),
which had antibodies against NS proteins by the 3ABC ELISA, no
challenge-virus replication was detected in this group. A slight
increase in the levels of SN antibodies was detected in the three
animals in this group after challenge (Table 2; Fig. 1). All animals
that received only the low vaccine dose (1107 pfu) developed
clinical disease (Fig. 2C), but one animal (♯13) had a low clinical
score (Table 2). Furthermore, all animals in this group were
positive in all the assays that evaluated challenge-virus replication
including detection in serum of antibodies against FMDV NS
proteins (3ABC and radioimmunoprecipitation [RIP]) and increase
in the SN antibody titer. In contrast, all the animals treated with
the low vaccine dose (1107 pfu) in combination with poly ICLC
were clinically protected (Fig. 2D) and did not show signs of
Table 1
Clinical performance of swine immunized with varying doses of Ad5-CI-A24-2B in the absence or presence of poly ICLC (experiment ♯1).
Vaccine Dosea (pfu) Adjuvantb Pig ♯ Clinical scorec Viremiad Shedding viruse SNf RT-PCRg
Ad5-Blue 2108 – 29 2/16 2/1.0105/2 2/8.2101/2 o0.3/3.0 SP
30 2/17 2/4.0105/3 2/5.6102/2 o0.3/3.0 SP
31 2/17 2/2.7105/2 2/8.2102/2 o0.3/3.3 SP
Ad5-CI-A24-2B 2108 – 12 0 0 0 1.2/2.4 N
13 0 0 0 1.2/2.1 N
14 0 0 0 1.2/2.1 N
Ad5-CI-A24-2B 4107 – 26 3/3 0 0 1.2/3.6 WP
27 3/2 0 0 1.2/4.2 N
28 6/1 0 0 0.9/3.6 WP
Ad5-CI-A24-2B 4107 pICLC 1 mg 23 0 0 0 1.5/3.0 N
24 6/1 0 0 1.2/3.9 N
25 6/1 0 0 1.2/3.3 N
Ad5-CI-A24-2B 4107 pICLC 4 mg 19 6/3 0 0 o0.3/3.3 N
20 5/2 0 0 1.2/3.3 WP
21 0 0 0
a Dose of inoculum per animal expressed as number of pfu in a total volume of 2 ml.
b Dose of adjuvant per animal in a total volume of 2 ml.
c dpc ﬁrst signs of lesions are detected/highest lesion score achieved throughout the entire experiment.
d First day post-challenge (dpc) that viremia was detected; maximum amount of viremia in pfu/ml detected in sera samples; and the duration (days) of viremia.
e First dpc that shedding virus was detected; maximum amount of shedding virus in pfu/ml detected in nasal swab samples; and the duration (days) of shedding.
f SN¼serum neutralizing antibody response reported as Log TCID50 at 0 and 21 dpc, respectively.
g RT-PCR, 1–7 dpc sera tested, N¼negative, Ct¼40; WP¼weak positive, 35rCto40; SP¼strong positive, Cto35.
Table 2
Clinical performance of swine immunized with varying doses of Ad5-CI-A24-2B in the absence or presence of poly ICLC (experiment ♯2).
Vaccine Dosea (pfu) Poly ICLCb Pig ♯ Clinical scorec Viremiad Shedding viruse SNf 3ABC ELISAg RT-PCRh 3D (RIP)i
Ad5-Blue 2108 – 16 2/15 1/6.0106/4 2/1.6104/4 o0.3/2.7 SP SP SP
17 2/13 1/6.3106/3 2/1.4103/2 o03/Dj D SP D
18 2/17 1/6.7106/3 2/7.8104/2 o0.3/D D SP D
Ad5-CI-A24-2B 2108 – 1 0 0 0 1.8/2.1 N N N
2 0 0 0 2.7/3.3 SP N N
3 0 0 0 2.1/2.4 N N N
Ad5-CI-A24-2B 1107 – 13 4/2 0 3/1.1103/4 1.8/2.7 WP SP SP
14 3/17 4/5.5102/1 2/6.5102/4 o0.3/2.7 SP SP WP
15 3/15 4/3.0102/1 3/1.3103/2 1.2/3.0 SP SP SP
Ad5-CI-A24-2B 1107 1 mg 10 0 0 0 1.5/2.4 N N N
11 0 0 0 1.5/2.4 N N N
12 0 0 0
a Dose of inoculum per animal expressed as number of pfu in a total volume of 2 ml.
b Dose of adjuvant per animal in a total volume of 2 ml.
c dpc ﬁrst signs of lesions are detected /highest lesion score achieved throughout the entire experiment.
d First day post-challenge (dpc) that viremia was detected; maximum amount of viremia in pfu/ml detected in sera samples; and the duration (days) of viremia.
e First dpc that shedding virus was detected; maximum amount of shedding virus in pfu/ml detected in nasal swab samples; and the duration (days) of shedding.
f SN¼serum neutralizing antibody response reported as Log TCID50 at 0 and 21 dpc, respectively.
g 3ABC ELISA, 21 dpc sera tested, N¼negative, 0–45; WP¼weak positive, 45–55; SP¼strong positive, 455.
h RT-PCR, 1–7 dpc sera tested, N¼negative, Ct¼40; WP¼weak positive, 35rCto40; SP¼strong positive, Cto35.
i Detection of serum antibodies against FMDV 3D protein tested by radioimmunoprecipitation at 21 dpc sera tested, N¼negative; WP¼weak positive; P¼positive;
SP¼strong positive.
j D¼animal ♯s 17 and 18 died on 4 dpc from FMD related causes.
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challenge-virus replication (Table 2). Interestingly, an increase in
the level of SN antibodies was detected after challenge of this
group, to levels similar to the protected animals treated with the
high dose of vaccine (Fig. 1).
Use of poly ICLC allows for an 80-fold dose sparing in the protective
Ad5-CI-A24-2B vaccine dose
Since the addition of poly ICLC allowed us to lower the protective
dose of vaccine by 20-fold (from 2108 to 1107 pfu), we next used
a 4-fold lower vaccine dose to test the limits of efﬁcacy of the
combination of vaccine and poly ICLC. In experiment ♯3, 4 groups
of 3 animals/group were vaccinated with 1107 pfu Ad5-Blue,
1107 pfu Ad5-CI-A24-2B plus 1 mg poly ICLC, 1107 pfu Ad5-CI-
A24-2B plus 0.5 mg poly ICLC, 2.5106 pfu Ad5-CI-A24-2B plus 1 mg
poly ICLC and challenged 21 dpv. Two additional groups were
vaccinated with 1107 pfu Ad5-CI-A24-2B plus 1 mg poly ICLC or
2.5106 pfu Ad5-CI-A24-2B plus 1 mg poly ICLC and challenged at
7 dpv (Table 3).
All animals vaccinated with 1107 pfu of Ad5-CI-A24-2B in
combination with different amounts of poly ICLC and challenged at
21 dpv developed SN antibodies prior to challenge with a peak at 14
dpv and maintained an SN response at the day of challenge (Fig. 3). In
contrast animals vaccinated with a lower dose (2.5106 pfu) and
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challenged at 21 dpv did not have a SN antibody response at the time
of challenge, even when the vaccine was combined with poly ICLC
(Fig. 3; Table 3). Likewise, none of the animals challenged at 7 dpv
developed detectable SN antibody response before challenge.
All animals in the control group developed viremia and clinical
disease by 2 dpc, and had detectable virus shedding by 3 dpc
(Fig. 4A; Table 3). In the group given vaccine at a dose of 1107 pfu
with 1 mg poly ICLC and challenged at 21 dpv one animal was
clinically and serologically protected, while the other 2 animals
developed a delayed and signiﬁcantly reduced severity of disease in
comparison to the control group. In these 2 animals viremia was not
detected by virus isolation, but viral RNA and FMDV-speciﬁc
antibodies were positive (Fig. 4B; Table 3). Animals given the same
dose of vaccine and 0.5 mg poly ICLC and also challenged at 21 dpv
were completely protected from clinical disease (Fig. 4C. Table 3)
and did not show signs of challenge-virus replication (Table 3).
Interestingly, when the vaccine dose was further reduced by 4-fold
to 2.5106 pfu and was used in combination with 1 mg of poly
ICLC, all animals challenged at 21 dpv were completely protected
from clinical disease (Fig. 4D), even in the absence of a SN antibody
response at the time of challenge (Fig. 3, Table 3). A weak positive
viral RNA level was detectable in these animals.
All animals in both groups challenged at 7 dpv showed clinical
signs, although there was a delay and reduced severity of disease in
the group given 1107 and poly ICLC as compared to the control
group (Fig. 4E). Although the group given 2.5106 pfu of vaccine and
poly ICLC, had similar, but slightly less severe disease than the control,
this group had approximately 10-fold less virus shedding (Fig. 4F).
Poly ICLC enhances the antigen speciﬁc T cell response induced by
Ad5-CI-A24-2B vaccine
In experiment ♯3, animals given an 80-fold reduced dose of
vaccine (2.5106 pfu) plus poly ICLC and challenged at 21 dpv did
Table 3
Clinical performance of swine immunized with varying doses of Ad5-CI-A24-2B combined with different amounts of poly ICLC and challenged at different days post-
vaccination (experiment ♯3).
Vaccine Dosea (pfu) pICLCb Pig♯ Clinical scorec Viremiad Shedding viruse SNf 3ABC ELISAg RT-PCRh 3D (RIP)i
Ad5-Blue challenge 21 dpi 1107 – 31478 2/16 2/8.5104/2 3/4.3102/1 o0.3/2.1 SP SP SP
31479 2/16 2/4.7105/2 3/4.6102/1 o0.3/1.8 P SP SP
31480 2/16 2/9.3104/2 3/3.0102/1 o0.3/2.4 P SP SP
Ad5-CI-A24-2B challenge 21 dpi 1107 1 mg 31463 4/3 0 3/5.0100/1 o0.3/1.8 SP WP SP
31464 0 0 0 0.9/1.5 N N N
31465 4/3 0 3/3.3101/1 0.9/2.1 WP WP WP
Ad5-CI-A24-2B challenge 21 dpi 1107 0.5 mg 31466 0 0 0 0.9/1.2 N N N
31467 0 0 0 0.9/1.2 N N N
31468 0 0 0 0.9/1.2 N N N
Ad5-CI-A24-2B challenge 7 dpi 1107 1 mg 31469 7/2 0 0 o0.3/1.8 N WP P
31470 4/9 0 0 o0.3/1.8 P WP P
31471 5/6 0 0 o0.3/1.8 WP WP SP
Ad5-CI-A24-2B challenge 21 dpi 2.5106 1 mg 31472 0 0 0 o0.3/Dj D D D
31473 0 0 0 o0.3/1.2 N WP N
31474 0 0 0 o0.3/1.2 N WP N
Ad5-CI-A24-2B challenge 7 dpi 2.5106 1 mg 31475 3/13 3/8.8103/2 3/2.0101/1 o0.3/1.8 WP SP SP
31476 4/10 0 3/2.0101/1 o0.3/2.4 SP SP SP
31477 2/14 3/1.42105/1 3/1.0101/1 o0.3/1.8 WP SP SP
a Dose of inoculum per animal expressed as number of pfu in a total volume of 2 ml.
b Dose of adjuvant per animal in a total volume of 2 ml.
c dpc ﬁrst signs of lesions are detected /highest lesion score achieved throughout the entire experiment.
d First day post-challenge (dpc) that viremia was detected; maximum amount of viremia in pfu/ml detected in sera samples; and the duration (days) of viremia.
e First dpc that shedding virus was detected; maximum amount of shedding virus in pfu/ml detected in nasal swab samples; and the duration (days) of shedding.
f SN¼serum neutralizing antibody response reported as Log TCID50 at 0 and 21 dpc, respectively. D¼died.
g 21 dpc sera tested, N¼negative; WP¼weak positive; P¼positive; SP¼strong positive.
h RT-PCR, 1–7 dpc sera tested, N¼negative Ct¼40; WP¼weak positive, 35rCto40; SP¼strong positive, Cto35.
i Detection of serum antibodies against FMDV 3D protein tested by radioimmunoprecipitation at 21 dpc sera tested, N¼negative; WP¼weak positive; P¼positive;
SP¼strong positive.
j Pig ♯31472 died at 3 dpc from other than FMD related causes.
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Fig. 3. Kinetics of neutralizing antibodies against FMDV A24 in pigs vaccinated with different doses of Ad5 vectors in combination with poly ICLC and challenged at 7 or 21
dpv (experiment ♯3). Serum samples were collected weekly following vaccination and challenge. Titers are expressed as the inverse dilution of serum yielding a 50%
reduction of virus titer (Log10 TCID50/ml). Dashed line represents limit of detection (values r0.3). Each data point represents the mean (7SD) of each group.
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not develop a stable SN antibody response, albeit they were
protected from clinical disease after challenge. We had previously
shown that the Ad5-FMD vaccine, at a dose of 5109 pfu, is able
to induce a T cell response in cattle and this response correlates
with protection in animals challenged 21 days after vaccination
(Moraes et al., 2011). We therefore examined if a T cell response
is induced and correlates with protection after vaccination of
swine with the Ad5-CI-A24-2B vaccine alone or in combination
with poly ICLC. Peripheral blood mononuclear cells (PBMCs) were
puriﬁed from most of the animals from experiments ♯2 and ♯3 at
different times post-vaccination and the percentage of speciﬁc
IFN-γ producing CD4þ and CD8þ cells was determined by FACS
analysis (Fig. 5)
In experiment ♯2 we observed that animals vaccinated with the
highest dose of vaccine alone (Ad5-CI-A24-2B; 2108 pfu) showed
a speciﬁc IFN-γ CD4þ and CD8þ T cell response prior to challenge,
with an immediate boost after challenge, and reaching a maximum
at 1–3 dpc as compared to the control group (Ad5-Blue; 2108 pfu)
(Fig. 5, B vs A). When the dose of vaccine was reduced by 20-fold
(Ad5-CI-A24-2B; 1107 pfu), the T cell response was considerably
lower than in the group with high dose vaccine, prior to and after
challenge (Fig. 5, D vs B), with statistically signiﬁcant differences for
CD4þ cells at days 3 and 5 dpc and for CD8þ cells at days 0 and
3 dpc (Pr0.05). However, when the same lower dose was used in
combination with 1 mg of poly ICLC, the IFN- γ producing CD8þ T
cell response increased and was statistically signiﬁcantly higher as
compared with the animals inoculated with the same dose of
vaccine without poly ICLC (Po0.01) (Fig. 5, panel C vs D) or with
the group inoculated with the highest dose of vaccine (Po0.05,
after challenge) (Fig. 5, C vs B). Although the same trend was
observed for IFN-γ producing CD4þ T cells, the differences were not
statistically signiﬁcant. Furthermore, analyses of the percentage of
the IFN-γ producing CD4þ and CD8þ cells in experiment ♯3 (Fig. 5,
E–H), showed that all animals treated with the Ad5-CI-A24-2B
vaccine in combination with poly ICLC had a speciﬁc response at
1 dpc which was statistically signiﬁcant as compared with the Ad5-
Blue control group (compare Fig. 5, F–H vs E ). However, when these
groups were compared with the animals inoculated with
2108 pfu of vaccine alone from experiment ♯2, the differences
were not statistically signiﬁcant (Fig. 5, F–H vs B), indicating that
giving less vaccine in combinationwith poly ICLC results in a similar
T cell response as a higher dose of vaccine alone. In addition,
animals inoculated with 2.5106 pfu Ad5-CI-A24-2B plus 1 mg of
poly ICLC developed a similar IFN-γ CD4þ/CD8þ speciﬁc response
even in the absence of a detectable SN antibody response at the
time of challenge.
Discussion
To be considered as a practical alternative, any novel FMD
vaccine candidate must address the shortcomings of the current
inactivated FMD vaccine and in addition, it has to be cost effective.
Our Ad5-vectored FMD vaccine only contains a portion of the
FMDV genome, and thereby it does not cause disease and can be
produced in non-containment BSL2 facilities. Animals vaccinated
Fig. 4. Clinical outcome of pigs vaccinated with different doses of Ad5 vectors in combination with poly ICLC and challenged at 7 or 21 dpv (experiment ♯3). Clinical signs
(bars), the presence of virus in serum (solid lines) and nasal swabs (dashed lines) were monitored daily for 7 dpc. Clinical score and virus levels are expressed as described in
Fig. 2 legend. The error bars represent the variation within the three animals from each group.
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with this agent can be unequivocally differentiated from infected
animals (DIVA). Furthermore, since the Ad5-FMD vaccine is
produced as a cDNA platform there is little concern about
antigenic variation arising during the manufacturing process as
compared to the current inactivated FMDV vaccine that relies on
the viral error-prone RNA polymerase (3D) for replication
(Domingo and Holland, 1988).
To address the economics of vaccine production we have
evaluated a number of approaches aiming to reduce the vaccine
dose required for complete protection. We previously demon-
strated that a single dose of our second generation Ad5-CI-A24-2B
vaccine can protect swine given 2108 pfu when delivered sc at
2 sites as compared to 5109 pfu when delivered im at 1 site
(Grubman et al., 2012), resulting in a 25-fold dose-sparing.
In this study we demonstrated, for the ﬁrst time, the potential
of using poly ICLC to enhance the protective response of a live
viral-vectored FMD vaccine. Our results show that addition of poly
ICLC to the Ad5-FMD vaccine allows for an additional 80-fold
reduction in the vaccine dose required for protection when swine
are challenged at 21 dpv.
Despite the animal to animal variation we demonstrated that
the addition of poly ICLC to groups given vaccine doses of 1107
or 2.5106 pfu and challenged at 21 dpv resulted in full protec-
tion in 9 out of 11 animals showing no clinical disease, no detec-
table viremia or virus shedding (Tables 2 and 3). The remaining
two animals had at least a 10-fold reduction in virus shedding
with delayed and signiﬁcantly reduced clinical signs as compared
to the control group. In one experiment (experiment ♯2) we had
observed that a combination of 1107 pfu and 1 mg of poly ICLC
was sufﬁcient to protect 3 animals when challenged at 21 dpv.
However although the same dose was not fully protective in the
next experiment (experiment ♯3), reduction of the amount of poly
ICLC from 1 to 0.5 mg, or the vaccine dose from 1107 to
2.5106 pfu provided the desired protection, but only when used
in combination. These results clearly indicated that poly ICLC
works as an effective adjuvant of the live Ad5 vectored FMD
vaccine. Of particular interest, animals given the lowest dose of
vaccine, 2.5106 pfu (experiment #3), did not have a detectable
FMDV-speciﬁc SN antibody response at the day of challenge albeit
they were clinically protected. Noticeably, these animals displayed
a CD4þ/CD8þ IFN-γ producing T cell response at 1 dpc as
compared to the control group. These results are consistent with
previous animal studies demonstrating that poly ICLC can work as
an adjuvant enhancing the antigen speciﬁc T cell response. Studies
comparing different TLR agonists in non-human primates have
shown that poly IC was the most efﬁcient in inducing SIV Gag-
speciﬁc CD4þ Th1 responses in blood and bronchoalveolar lym-
phocytes with a signiﬁcant induction of a CD8þ T cell response
after boosting; further, animals were completely protected against
SIV challenge (Park et al., 2013). Recently, Martins et al. (2014)
have reported that a strong antigen speciﬁc polyfunctional CD4þ/
CD8þ T cell response is induced when a virus-like particle vaccine
is used in combination with poly ICLC signiﬁcantly enhancing
protection against Ebola virus infection. Most importantly, and
similar to our previous studies in cattle, (Moraes et al., 2011), the
results presented here suggest that a CD4þ/CD8þ T cell response
Fig. 5. Cell-mediated immunity induced in pigs vaccinated with different doses of Ad5 vectors with or without poly ICLC and challenged at 21 dpv (experiment ♯2 [panels A–D]
and ♯3 [panels E–H]). Speciﬁc cellular response was measured by intracellular cytokine staining (ICCS). PBMCs from vaccinated and control animals were extracted at different
times during vaccination (dpv) and after challenge (dpc) with FMDV A24, stimulated with homologous FMDV A24 ex vivo and the capacity of CD4þ or CD8þ T cells to produce
IFN-γ was evaluated by ICCS. The percentage of CD4þ or CD8þ T cells that produce IFN-γ is shown. The error bars represent the variation within the three animals from
each group.
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may play an important role in improving the Ad5-FMD elicited
protection against FMDV challenge in swine, and the addition of
poly ICLC can further boost this response.
Animals challenged at 7 dpv also did not develop a detectable
SN antibody response, but had delayed and/or less severe clinical
disease as compared to the control group (Table 3). The group
inoculated with 1107 pfu vaccine plus poly ICLC had no detect-
able viremia or virus in nasal swabs and clinical signs were
delayed 2–5 days. The group inoculated with a 4-fold lower
vaccine dose had more severe disease, but clinical signs and virus
shedding were less severe than the control group indicating that
even at such a low vaccine dose the presence of poly ICLC
ameliorated disease severity as early as 7 dpv.
Two other groups have also recently tested the effectiveness of
poly IC as an adjuvant for FMD vaccines. Cao et al. (2013) combined
poly IC with a multiple epitope FMD protein vaccine resulting in
100% protection against clinical disease of swine challenged at 28
dpv as compared to 60% protection of swine vaccinated with the
vaccine alone. In parallel experiments, the same group evaluated
cross-protection in pigs against different topotypes of FMDV serotype
O using a multi-epitope subunit vaccine emulsiﬁed in oil in combi-
nation with poly IC. The animals were clinically protected evenwhen
the dose of vaccine was reduced 9-fold (Cao et al., 2014). Furthemore,
Zhou et al. (2014) inoculated mice with aluminum hydroxide
adjuvanted inactivated FMD vaccine and examined the effect of the
addition of either poly IC, or resiquimod – a TLR7 agonist, or both, on
the immune response. They found a small immune enhancement
with the addition of only poly IC compared to vaccine and aluminum
hydroxide, but a signiﬁcant enhancement when both, poly IC and
resiquimod, were added.
Our data clearly indicates that poly ICLC can also work as an
adjuvant of a live vectored Ad5-FMD vaccine. Addition of poly ICLC
allowed for an Ad5-CI-A24-2B vaccine dose sparing of approxi-
mately 2000-fold compared to the dose used in our initial studies
with our ﬁrst generation Ad5-A24 vaccine (Grubman et al., 2010).
Poly ICLC is more stable than naked poly IC and resists nucleases
that are present in the serum of mammals (Nordlund et al., 1970,
Levy et al., 1975). Our demonstration that this compound has an
adjuvant effect when administered in combination with the Ad5-
FMD vectored vaccine makes this approach more practical,
although the cost of poly ICLC needs to be considered. In this
regard we found that one swine group given 0.5 mg poly ICLC was
as well protected as the group administered with 1 mg poly ICLC
(Table 3). Future studies to determine the minimum amount of
poly ICLC required to induce protection with a relative low vaccine
dose (i.e. 2.5106 pfu), as well as the identiﬁcation of other
adjuvants that could provide the effectiveness of poly ICLC at an
economically reasonable cost are within our immediate scope in
evaluating countermeasures against FMD.
Materials and methods
Cells and viruses
Human 293 cells (ATTC CRL-1573) from the American Type
Culture Collection (ATCC; Rockville, MD) were used to generate,
grow and titer all recombinant human Ad5 viruses used in this
study (Graham and Prevec, 1991; de Avila Botton et al., 2006). The
recombinant Ad5 viruses included: Ad5-Blue, a negative control
containing the α gene fragment of β-galactosidase (Moraes et al.,
2001) and Ad5-CI-A24-2B, which contains the FMDV A24 P1-2A
and full-length 2B coding regions and the 3B (lacking the ﬁrst
6 amino acids of 3B1) and 3Cpro coding regions of FMDV A12 under
the control of the cytomegalovirus promoter/enhancer, intron, and
T7 RNA polymerase region from the vector pCI (Promega, Madison,
WI) (Pena et al., 2008). All Ad5 vectors were puriﬁed by CsCl
gradient centrifugation and viral titer determined by standard
protocols (de Avila Botton et al., 2006). To measure FMDV
transgene expression swine kidney cells, IB-RS-2 cells, were
infected with Ad5-CI-A24-2B and cell lysates were examined by
Western blot analysis with a polyclonal antibody to detect FMDV
structural proteins. Plaque reduction neutralization assays and
FMDV titration from blood and nasal swabs samples were per-
formed on BHK-21 cells (ATCC CCL-10). FMDV A24 Cruzeiro used
as a challenge virus in this study was collected from the vesicular
ﬂuid of an infected swine and titered in IB-RS-2 cells and in pigs
and stored in aliquots at 70 1C. Poly ICLC was provided by
Oncovir, Inc.
Vaccine trials in swine
Three vaccine experiments were performed in the high-
containment facilities of the Plum Island Animal Disease Center
(PIADC) under animal protocol number 151-10-R that was
approved by the Institutional Animal Care and Use Committee of
PIADC (USDA/APHIS/AC Certiﬁcate number: 21-F-0001). Animals
were acclimated for 5–7 days before the start of the experiments.
In all experiments, female Yorkshire swine (ﬁve weeks old and
weighing approximately 40–50 lbs each) were divided into groups
according to the vaccination regimen and each group was housed
in separate rooms. All animals were vaccinated sc at two sites on
either side of the neck with a total volume of 2 ml of a formulation
containing various amounts of Ad5-CI-A24-2B and poly ICLC
diluted in PBS, when applicable (Grubman et al., 2012).
In all the experiments the immunogenicity and efﬁcacy of the
vector were tested, at varying doses, in the absence or presence of
varying amounts of poly ICLC. In experiment ♯1, 15 pigs were
divided into 5 groups. The ﬁrst 2 groups were inoculated with
2108 pfu/animal Ad5-Blue or Ad5-CI-A24-2B, respectively, while
the other three groups were inoculated with 4107 pfu/animal
Ad5-CI-A24-2B in the absence or presence of 1 or 4 mg poly ICLC.
Twenty-one dpv all pigs were challenged intradermally (id) in the
heel bulb in the left rear foot (4 inoculation sites of 100 μl each)
with a total of 1105 pfu/animal of FMDV A24 Cruzeiro.
In experiment ♯2, 12 pigs were divided into 4 groups. The ﬁrst
2 groups were inoculated with 2108 pfu/animal Ad5-Blue or
Ad5-CI-A24-2B, respectively, while the third and fourth groups
were inoculated with 1107 pfu/animal Ad5-CI-A24-2B in the
absence or presence of 1 mg poly ICLC, respectively. Twenty-one
dpv all pigs were challenged as above.
In experiment ♯3, 18 pigs were divided into 6 groups. The ﬁrst
group was treated with 1107 pfu/animal Ad5-Blue, the second
and third groups were treated with 1107 pfu/animal Ad5-CI-
A24-2B plus 1 or 0.5 mg poly ICLC, respectively, the fourth group
was treated with 1107 pfu/animal Ad5-CI-A24-2B plus 1 mg
poly ICLC, and the ﬁfth and sixth groups were treated with
2.5106 pfu/animal Ad5-CI-A24-2B plus 1 mg poly ICLC. Groups
1, 2, 3 and 5 were challenged at 21 dpv and groups 4 and
6 challenged at 7 dpv as above.
Serum samples were collected from all animals weekly until
the termination of the experiment (21 dpc), when the animals
were humanely euthanized. Serum samples were inactivated at
56 1C for 30 min.
After challenge, animals were examined daily for 7 days and a
clinical score was recorded. A ﬁnal clinical examination was
performed at 14 dpc. Rectal temperature data was monitored on
a daily basis throughout the experiment. Clinical scores were
determined by the number of toes presenting FMD lesions plus
the presence of lesions in the snout and/or mouth. The maximum
score was 17, and lesions restricted to the site of challenge were
not counted.
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Nasal swabs and serum samples were taken daily for seven
days after challenge to assess virus shedding and viremia, respec-
tively. Heparinized blood was obtained weekly after vaccination
and on 1, 3, 5, 7, 14 and 21 dpc to extract PBMCs to study the
cellular immune response.
Evaluation of humoral and cellular immune responses
Determination of serum neutralizing (SN) antibody titer
Sera samples were tested for the presence of FMDV-speciﬁc SN
antibodies by a plaque reduction neutralization assay (PRN) as
previously described (Mason et al., 1997). Serum neutralizing
antibody titers were reported as the serum dilution yielding a
50% reduction in the number of plaques (TCID50) induced by FMDV
A24 Cruzeiro in BHK-21 cells.
Flow cytometry analysis
CD8þ and CD4þ IFN-γ-producing cells in total PBMCs were
prepared and analyzed by ﬂow cytometry as previously described
(Díaz-San Segundo et al., 2012). Expression of cell surface mole-
cules was analyzed using mouse anti-swine CD4-FITC and mouse
anti-swine CD8-AF647 (AbD Serotec, Raleigh, NC).
3ABC ELISA assay
Zero and 21 dpc sera were examined for antibodies against
FMDV NS protein 3ABC using a PrioCHECK™ FMDV-NS ELISA kit
(Prionics AG, Lelystad, Netherlands) (Sorensen et al., 1998).
Radioimmunoprecipitation (RIP) of [35S]methionine/cysteine labeled
FMDV A24 infected cell lysates
Sera obtained at 0 and 21 dpc were tested for antibodies
against FMDV NS proteins by a RIP assay as previously described
(Wu et al., 2003).
Virus titration in blood and nasal secretions
Serum samples and nasal swabs were assayed for the presence
of virus by a standard plaque assay on BHK-21 cells (passage levels
60–70) (Moraes et al., 2007). Virus titers were expressed as log10
pfu per ml of blood or nasal swab.
Detection of FMDV RNA by real-time RT-PCR (rRT-PCR)
Serum samples from animals that had no detectable clinical
disease were processed for RNA extraction and rRT-PCR as
described (Arzt et al., 2010). Samples were considered positive
when Ct values were o40.
Statistical analysis
Statistical signiﬁcance of differences was evaluated by Student's
t test. Differences were considered signiﬁcant for Po0.05.
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